KDR and Hypertension: In contrast, CC-509 inhibits KDR cell activity to comparable levels at 10-fold higher concentrations than R406 and at levels reached only briefly at minimum efficacious exposures in rodents (data not shown), suggesting it would be unlikely to trigger KDR-dependent hypertension in human patients.